Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

Petrelintide is part of an emerging class of drugs that bind to and activate the amylin receptor. The once-weekly injectable Zealand drug is a peptide engineered to be a long-acting version of ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

“Amylin’s innovative diabetes portfolio ... develop and commercialise select investigational drugs for type 2 diabetes. Their collaboration is primarily focused around ONGLYZA (saxagliptin ...

Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which ...

For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal ...

Roche is in-licensing co-development and co-commercialization rights to Denmark’s Zealand Pharma’s long-acting amylin analog, petrelintide, being developed in phase IIb studies for people who ...